Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLSD Clearside Biomedical	$0.39 +0.2%	$0.58	$0.29 ▼ $1.65	$30.35M	2.08	497,159 shs	858,932 shs
DYAI Dyadic International	$0.91 -2.5%	$0.95	$0.71 ▼ $2.20	$33.69M	0.89	147,157 shs	16,446 shs
ITRM Iterum Therapeutics	$0.69 -4.2%	$0.86	$0.66 ▼ $3.02	$32.24M	2.85	1.06 million shs	664,142 shs
KZIA Novogen	$7.73 -1.0%	$8.28	$2.86 ▼ $39.05	$7.87M	2.64	64,467 shs	17,271 shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLSD Clearside Biomedical	-2.20%	-5.15%	-13.14%	-50.44%	-61.72%
DYAI Dyadic International	+2.91%	+14.94%	-16.13%	-10.05%	-37.52%
ITRM Iterum Therapeutics	+5.66%	-4.96%	-7.44%	-26.33%	-35.54%
KZIA Novogen	-3.34%	+11.57%	-8.87%	+104.72%	-64.22%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership
CLSD Clearside Biomedical	2.6805 of 5 stars	4.1	3.0	3.5	0.0
DYAI Dyadic International	3.4286 of 5 stars	3.5	5.0	2.7	3.3
ITRM Iterum Therapeutics	2.1928 of 5 stars	3.5	3.0	1.9	1.7
KZIA Novogen	3.743 of 5 stars	3.8	5.0	2.2	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLSD Clearside Biomedical	2.17	Hold	$4.20	984.15% Upside
DYAI Dyadic International	3.00	Buy	$6.00	561.23% Upside
ITRM Iterum Therapeutics	3.00	Buy	$9.00	1,200.58% Upside
KZIA Novogen	3.50	Strong Buy	$14.00	81.11% Upside

Current Analyst Ratings Breakdown

Latest KZIA, CLSD, ITRM, and DYAI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/18/2025	CLSD Clearside Biomedical	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$5.00
7/18/2025	CLSD Clearside Biomedical	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
7/18/2025	CLSD Clearside Biomedical	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$2.00
7/17/2025	CLSD Clearside Biomedical	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/17/2025	CLSD Clearside Biomedical	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Moderate Buy ➝ Hold	$3.00
7/10/2025	KZIA Novogen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy ➝ Strong-Buy	$13.00
6/11/2025	KZIA Novogen	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00

(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLSD Clearside Biomedical	$1.66M	18.32	N/A	N/A	($0.62) per share	-0.62
DYAI Dyadic International	$3.49M	9.41	N/A	N/A	($0.01) per share	-90.74
ITRM Iterum Therapeutics	N/A	N/A	N/A	N/A	($0.09) per share	N/A
KZIA Novogen	$1.51M	5.17	N/A	N/A	($9.87) per share	-0.78

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLSD Clearside Biomedical	-$34.35M	-$0.37	N/A	N/A	N/A	-665.19%	N/A	-124.15%	11/11/2025 (Estimated)
DYAI Dyadic International	-$5.81M	-$0.19	N/A	N/A	N/A	-134.84%	-355.39%	-60.66%	11/11/2025 (Estimated)
ITRM Iterum Therapeutics	-$24.77M	-$0.85	N/A	∞	N/A	N/A	N/A	-65.01%	11/13/2025 (Estimated)
KZIA Novogen	-$17.56M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest KZIA, CLSD, ITRM, and DYAI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	DYAI Dyadic International	-$0.06	-$0.06	N/A	-$0.06	$0.60 million	$0.97 million
8/8/2025	Q2 2025	CLSD Clearside Biomedical	-$0.12	-$0.06	+$0.06	-$0.06	$0.50 million	$0.49 million
8/5/2025	Q2 2025	ITRM Iterum Therapeutics	-$0.13	-$0.16	-$0.03	-$0.16	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLSD Clearside Biomedical	N/A	N/A	N/A	N/A	N/A
DYAI Dyadic International	N/A	N/A	N/A	N/A	N/A
ITRM Iterum Therapeutics	N/A	N/A	N/A	N/A	N/A
KZIA Novogen	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLSD Clearside Biomedical	N/A	3.87	3.87
DYAI Dyadic International	5.40	2.02	2.02
ITRM Iterum Therapeutics	N/A	2.69	2.52
KZIA Novogen	N/A	0.21	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CLSD Clearside Biomedical	18.75%
DYAI Dyadic International	27.95%
ITRM Iterum Therapeutics	9.21%
KZIA Novogen	30.89%

Insider Ownership

Company	Insider Ownership
CLSD Clearside Biomedical	6.70%
DYAI Dyadic International	29.50%
ITRM Iterum Therapeutics	2.40%
KZIA Novogen	1.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CLSD Clearside Biomedical	30	78.51 million	73.25 million	Optionable
DYAI Dyadic International	7	36.19 million	25.51 million	Optionable
ITRM Iterum Therapeutics	10	44.66 million	43.59 million	Not Optionable
KZIA Novogen	12	1.01 million	997,000	Optionable

KZIA, CLSD, ITRM, and DYAI Headlines

Recent News About These Companies

Critical Contrast: Novogen (NASDAQ:KZIA) & Windtree Therapeutics (NASDAQ:WINT)

August 22, 2025 | americanbankingnews.com

Kazia Therapeutics Announces $2 Million Private Placement at Premium to Market

August 1, 2025 | prnewswire.com

Kazia Therapeutics Reports Early Efficacy Data from First Triple-Negative Breast Cancer Patient Receiving Paxalisib Combination Regimen achieving >50% Reduction in Circulating Tumor Cells in Phase 1b Trial

July 9, 2025 | prnewswire.com

Kazia Therapeutics Shares Jump After Data Shows Lead Asset Could Treat Breast Cancer

June 11, 2025 | marketwatch.com

Kazia Therapeutics Announces Transformative Preclinical Data Demonstrating Paxalisib's Potential to Overcome Immunotherapy Resistance in Triple-Negative Breast Cancer (TNBC)

June 11, 2025 | prnewswire.com

Kazia Therapeutics Announces First Patient Dosed in Phase 1b Trial of Paxalisib in Advanced Breast Cancer

June 5, 2025 | prnewswire.com

Kazia Therapeutics Highlights Recent Progress and Provides Business Update

May 15, 2025 | prnewswire.com

Vivesto AB: Vivesto signs deal with Kazia Therapeutics to acquire full Cantrixil rights

March 31, 2025 | finanznachrichten.de

Kazia Therapeutics sells IP, trademarks rights to Cantrixil for $1M

March 31, 2025 | markets.businessinsider.com

Kazia Therapeutics Announces Sale of Intellectual Property and Trademarks Rights for Cantrixil

March 31, 2025 | prnewswire.com

Kazia Therapeutics announces research grant awarded from MJFF

February 20, 2025 | markets.businessinsider.com

Maxim Group Initiates Coverage of Kazia Therapeutics Limited - Depositary Receipt () (KZIA) with Buy Recommendation

February 8, 2025 | msn.com

Maxim starts Kazia Therapeutics at Buy amid ‘positive’ GBM study data

February 6, 2025 | markets.businessinsider.com

Kazia Therapeutics initiated with a Buy at Maxim

February 6, 2025 | markets.businessinsider.com

Kazia Therapeutics Launches Clinical Trial Evaluating Paxalisib in Combination with Keytruda or Lynparza for the Treatment of Advanced Breast Cancer

January 31, 2025 | appliedclinicaltrialsonline.comA

Is Kazia Therapeutics (KZIA) One of the Best ASX Stocks to Buy According to Hedge Funds?

January 31, 2025 | msn.com

Kazia Therapeutics launches trial of paxalisib/immunotherapy combination

January 30, 2025 | markets.businessinsider.com

Why Kazia Therapeutics (KZIA) Is Surging: A Big Bet on Breast Cancer Breakthroughs

January 30, 2025 | bovnews.comB

Kazia Therapeutics announces the launch of a groundbreaking trial with paxalisib in combination with immunotherapy in women with advanced breast cancer

January 30, 2025 | prnewswire.com

Why Kazia Therapeutics (KZIA) Is Among the Best Australian Stocks to Buy Now?

January 27, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KZIA, CLSD, ITRM, and DYAI Company Descriptions

Clearside Biomedical NASDAQ:CLSD

$0.39 +0.00 (+0.21%)

Closing price 04:00 PM Eastern

Extended Trading

$0.38 -0.01 (-2.68%)

As of 07:56 PM Eastern

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

Dyadic International NASDAQ:DYAI

$0.91 -0.02 (-2.53%)

Closing price 04:00 PM Eastern

Extended Trading

$0.91 +0.00 (+0.29%)

As of 06:16 PM Eastern

Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein produced using the C1 platform. It has also developed the Dapibus thermophilic, a filamentous fungal-based microbial protein production platform to enable the development and large-scale manufacture of cost-effective proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, including food, nutrition, and wellness. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; Joint Development Agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.

Iterum Therapeutics NASDAQ:ITRM

$0.69 -0.03 (-4.16%)

Closing price 04:00 PM Eastern

Extended Trading

$0.69 0.00 (-0.14%)

As of 07:54 PM Eastern

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

Novogen NASDAQ:KZIA

$7.73 -0.08 (-1.02%)

Closing price 03:59 PM Eastern

Extended Trading

$7.98 +0.25 (+3.23%)

As of 05:19 PM Eastern

Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company's lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time